Vaxcyte, Inc. (PCVX) Cash Flow Statement
Vaxcyte, Inc. (PCVX) generated -$881.2M of operating cash flow over the twelve months to 2026-06-30, spent $39.8M on capital expenditure and had free cash flow of -$921.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PCVXVaxcyte, Inc.Follow PCVX — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -0.05 | -0.12 | -0.17 | -0.30 | -0.45 | -0.66 | -0.88 | |
| Capital expenditure | 0.00 | 0.01 | 0.01 | 0.07 | 0.12 | 0.06 | -0.04 | |
| Free cash flow | -0.05 | -0.13 | -0.18 | -0.36 | -0.57 | -0.71 | -0.92 | |
| Stock-based compensation | 0.01 | 0.01 | 0.02 | 0.05 | 0.08 | 0.14 | — |
USD billions · SEC XBRL
Vaxcyte, Inc. — questions
- What is Vaxcyte, Inc.'s operating cash flow?
- -$881.2M over the twelve months to 2026-06-30.
- How much does Vaxcyte, Inc. spend on capital expenditure?
- $39.8M over the twelve months to 2026-06-30.
- What is Vaxcyte, Inc.'s free cash flow?
- -$921.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Vaxcyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.